Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SMART: Pioglitazone metformin for MAFLD-related cirrhosis
NCT06135584Not yet recruiting
- Sponsor
- Affiliated Hospital of Hangzhou Normal University
- Start
- Nov 2023
- Primary completion
- Dec 2026
- Modality
- Small Molecules
01
Overview
Open-label trial of metformin + pioglitazone in metabolic dysfunction associated fatty liver disease (MAFLD) and Cirrhosis, sponsored by Affiliated Hospital of Hangzhou Normal University. Primary endpoint: Controlled attenuation parameter at 96 weeks. Planned start Nov 2023; status: not yet recruiting.
02
Drugs
metformin + pioglitazone
03
Conditions
metabolic dysfunction associated fatty liver disease (MAFLD)Cirrhosis
Beyond the preview
Go deeper on NCT06135584.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06135584.